Press Release
Category Added in a WPeMatico Campaign
-
Mozilla Foundation Brings Hollywood’s AI and IP Reckoning Into the Open
Los Angeles marks the latest, and most legally charged, stop in Mozilla Foundation’s global Imaginative Intelligences series. LOS ANGELES, April…
Read More » -
Laminar Wins Gold 2026 Edison Award for Physical AI that Powers the Self-Driving Factory
Top honor recognizes Laminar’s innovation and transformation in the CPG manufacturing industry BOSTON, April 22, 2026 /PRNewswire/ — Laminar, a physical…
Read More » -
Quote.com Announces New Senior Leadership Additions
ST. PETERSBURG, Fla., April 22, 2026 /PRNewswire/ — Quote.com, a leading tech-enabled, omnichannel performance marketing organization, today announced the addition…
Read More » -
NewPower Worldwide Named a Partner of the Year at HPE 2026 Partner Summit
NASHUA, N.H., April 22, 2026 /PRNewswire/ — NewPower Worldwide today announced it was recognized by Hewlett Packard Enterprise (HPE) at…
Read More » -
Ada Health Clinical AI Turns Symptom Uncertainty Into Appropriate Action, Finds NEJM AI Study Conducted with CUF in Portugal
Real-world study at CUF, Portugal’s largest private healthcare network: Ada’s accurate, medical-grade assessment changed the behavior of 3 in 5…
Read More » -
Boost.ai Achieves SOC 2 Type II Certification for Enterprise Grade Conversational AI Platform
Clean audit report with zero exceptions accelerates procurement for global banking and insurance leaders. SANDNES, Norway, April 22, 2026 /PRNewswire/…
Read More » -
Boost.ai Achieves SOC 2 Type II Certification for Enterprise Grade Conversational AI Platform
Clean audit report with zero exceptions accelerates procurement for global banking and insurance leaders. SANDNES, Norway, April 22, 2026 /PRNewswire/…
Read More » -
Amperos Health Secures $16M Investment as it Launches Industry’s First AI-Native Denial Management and Revenue Recovery Platform
Helping providers resolve denials five times faster and cut denial rates by 70% NEW YORK, April 22, 2026 /PRNewswire/ —…
Read More » -
IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)
Through 120 weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including…
Read More » -
Companies Are Sitting on Talent They Can’t See or Unlock, TalentLMS Finds
The data reveals widespread talent underuse; 50% of respondents agree that their company hires externally for skills that current employees…
Read More »






